Using adaptive optics to improve retinal imaging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of adaptive optics in capturing detailed images of the retina to enhance the diagnosis and management of retinal diseases. Participants, including individuals with eye diseases and healthy volunteers aged 12 and older, will undergo comprehensive eye exams and adaptive optics imaging at the National Eye Institute. The study will compare retinal images from healthy and diseased eyes to identify potential diagnostic improvements. The research will span five years and involve a total of 600 participants.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

Participants will be eligible if they:

* Are 12 years of age or older.
* Have the ability to cooperate with an eye exam and adaptive optics imaging.
* Have the ability to understand and sign an informed consent or have a parent/legal guardian to do so if they are minor children.
* Have an eye disease or are a healthy volunteer with a normal eye exam (no visually-significant eye findings on examination).

EXCLUSION CRITERIA:

Participants will not be eligible if:

-They have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity).

EXCLUSION CRITERIA FOR FLUORESCEIN AND/OR INDOCYANINE GREEN IMAGING

Partaicipants are not eligible for fluorescein and/or indocyanine green imaging if they:

* Are under 18 years of age.
* For participants who will undergo fluorescein imaging have a history of adverse reaction to fluorescein.
* For participants who will undergo indocyanine green imaging have a history of adverse reaction to indocyanine green dye, know or suspected allergies to iodine or shellfish.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Johnny C Tam, Ph.D. — National Eye Institute (NEI)
• Study coordinator: Daniel W Claus, R.N.
• Email: daniel.claus@nih.gov
• Phone: (301) 451-1621

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Autologous Serum Tears with Hyaluronate vs Standard Serum Tears for Moderate-to-Severe Dry Eye

  This study tests whether adding sodium hyaluronate to autologous serum eye drops provides better relief for adults with moderate-to-severe dry eye in one eye, compared with the standard serum drops in the other eye.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07413172

• Two approaches to repeat eyelid surgery for post-operative trichiasis

  This project will try whether the newer Bevel-Rotate Advancement Procedure (B-RAP) or the standard Bilamellar Tarsal Rotation (BLTR) gives better results for people in Tanzania who need repeat surgery for post-operative trachomatous trichiasis.

  Recruiting at 2 sites University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07322302

• How TRYPTYR affects quality of life and the ability to work for people with dry eye

  This one-month test will see if TRYPTYR (acoltremon) eye drops help adults with chronic dry eye produce more tears, reduce symptoms, and improve their ability to do work.

  Recruiting at 3 sites Phase 4 Southern College of Optometry · Pittsburg, Kansas and 2 other locations · NCT07266948

• Course of EYS-associated retinitis pigmentosa in adults from Russia and former CIS

  We will follow adults with pathogenic EYS gene variants from Russia and former CIS for four years to try to find reliable vision and retinal measures for future treatments.

  Recruiting Sensor Technology for Deafblind · Moscow · NCT07228793

• Dapagliflozin (an SGLT2 inhibitor) for slowing geographic atrophy in dry AMD

  This trial will test whether taking dapagliflozin once daily can slow the growth of geographic atrophy in people aged 50 and older with dry age-related macular degeneration.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07174687

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.